Login
Companies $RNAC
$6.10 +$0.02 (0.33%) Pre-market
Cartesian Therapeutics, Inc. logo

Cartesian Therapeutics, Inc.

cartesiantherapeutics.com

What Do They Do?

Develops mRNA-modified CAR-T cell therapies for autoimmune diseases, including myasthenia gravis and myositis, for patients receiving treatment from physicians.

How Do They Make Money?

FY2025 revenue

Who Are Their Customers?

The company develops therapies for autoimmune diseases, with treatment administered to patients by their treating physicians. Its revenue has come primarily from collaborators and licensees funding research and development through upfront and milestone payments, royalties, and expense reimbursements.

Do Revenues Turn Into Profits?

No. It lost $130.3M in FY2025.

Operating income, FY2025
−5127% of revenue
▼ −227% (Loss) vs FY2024 (−$43.9M, −113%)
Net income, FY2025
−4659% of revenue
▼ −68% (Loss) vs FY2024 (−$77.4M, −199%)
Free cash flow, FY2025
−2839% of revenue
▼ −142% (Loss) vs FY2024 (−$32.8M, −84%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▼ −100%
vs $452K in Q3 FY2025
Net income
▲ +68% (Loss)
vs −$35.9M in Q3 FY2025
  • Jun 9, 2026 Cartesian licensed its mRNA payloads to WestGene for in vivo CAR-T development WestGene will pay an upfront fee and may owe development and commercial milestone payments.

Shrinking. Revenue fell 97% in 4 years, from $85.1M in FY2021 to $2.8M in FY2025, about 57% a year.

From immune-tolerance platforms to mRNA cell therapy The older report described ImmTOR-based therapies for biologic and gene therapy applications and autoimmune disease. The latest report centers on mRNA-modified CAR-T cell therapy candidates for autoimmune diseases.

Who Do They Compete With?

Competes with Amgen, Argenx, UCB, Johnson & Johnson, AstraZeneca, Kyverna Therapeutics, Cabaletta Bio, Novartis, Gilead Sciences, and Bristol-Myers Squibb

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support